Researchers from Integra Therapeutics, in collaboration with Pompeu Fabra University and the Center for Genomic Regulation, have experimentally validated synthetic proteins engineered via generative AI, surpassing natural proteins in efficiency for genome editing applications. This breakthrough exemplifies the unprecedented potential of AI to innovate at the molecular level, enhancing the capabilities of gene editing tools vital for therapeutic development and synthetic biology.